Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Auristatin F is a potent synthetic cytotoxic small molecule and a member of the auristatin family, derived from the natural product dolastatin 10. It acts as a microtubule inhibitor by binding to tubulin and inhibiting its polymerization, which leads to cell cycle arrest and apoptosis. Structurally, it is closely related to monomethyl auristatin F (MMAF) but features two methyl substituents on the N-terminal amino group. In addition to its antimitotic effects, auristatin F functions as a vascular damaging agent (VDA). Due to its extreme systemic toxicity, auristatin F is primarily utilized as a cytotoxic payload in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy, where it is linked to monoclonal antibodies to ensure selective delivery to malignant cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on auristatin F.